

Luiz Eduardo Wildemberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3684901/publications.pdf>

Version: 2024-02-01

14
papers

431
citations

933410

10
h-index

1058452

14
g-index

14
all docs

14
docs citations

14
times ranked

475
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatostatin receptor ligands in the treatment of acromegaly. <i>Pituitary</i> , 2017, 20, 100-108.	2.9	91
2	Predictors of surgical outcome and early criteria of remission in acromegaly. <i>Endocrine</i> , 2018, 60, 415-422.	2.3	61
3	MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. <i>European Journal of Endocrinology</i> , 2018, 178, R89-R100.	3.7	56
4	Apoplexy in nonfunctioning pituitary adenomas. <i>Pituitary</i> , 2018, 21, 138-144.	2.9	47
5	The Future of Somatostatin Receptor Ligands in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 297-308.	3.6	35
6	Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2047-2056.	3.6	27
7	Pasireotide for the treatment of acromegaly. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 579-588.	1.8	24
8	Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. <i>Clinical Endocrinology</i> , 2018, 88, 889-895.	2.4	21
9	Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. <i>Scientific Reports</i> , 2019, 9, 1122.	3.3	21
10	Molecular evidence and clinical importance of β -arrestins expression in patients with acromegaly. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2110-2116.	3.6	18
11	gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. <i>Cancers</i> , 2021, 13, 4857.	3.7	10
12	Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. <i>Hormones</i> , 2017, 16, 84-91.	1.9	9
13	Prolactinomas. <i>Presse Medicale</i> , 2021, 50, 104080.	1.9	8
14	Precision medicine in the medical management of pituitary tumors. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 1, 57-62.	1.4	3